Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-R in MYC Positive DLBCL
NCT01914718Phase 2Terminated
- Sponsor
- Fudan University
- Start
- Feb 2013
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, etoposide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection, cyclophosphamide in diffuse large B-cell lymphoma (DLBCL), sponsored by Fudan University. Started Feb 2013; status: terminated.
02
Drugs
rituximabetoposidepegylated liposomal doxorubicinvincristine sulfate liposome injectioncyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01914718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01914718.